

ESTTA Tracking number: **ESTTA595664**

Filing date: **03/31/2014**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	92052897
Party	Defendant Galderma Laboratories, Inc.
Correspondence Address	JEFFREY M BECKER HAYNES AND BOONE LLP 2323 VICTORY AVENUE, SUITE 700 DALLAS, TX 75219 UNITED STATES jeff.becker@haynesboone.com, Lisa.Congleton@haynesboone.com
Submission	Defendant's Notice of Reliance
Filer's Name	Lisa Normand Congleton
Filer's e-mail	ipdocketing@haynesboone.com, lisa.congleton@haynesboone.com, kathy.mettee@haynesboone.com
Signature	/Lisa Normand Congleton/
Date	03/31/2014
Attachments	Galderma_Notice of Reliance.pdf(5725833 bytes)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

REGISTRANT'S NOTICE OF RELIANCE

Pursuant to Rule 2.122 of the Trademark Rules of Practice, Registrant Galderma Laboratories, Inc. hereby introduces into evidence, and will rely upon, the attached documentation, as outlined below:

- A. Pursuant to TBMP § 704.03, Registrant hereby introduces into evidence, as Exhibits 1 – 5, copies of foreign trademark registrations filed in the name of CollaGenex International Ltd. in January 2002. These trademark registrations evidence the parties' understanding at the time these filings were made that Registrant's predecessor-in-interest, CollaGenex, was the sole and exclusive owner of the RESTORADERM mark pursuant to a Letter of Intent executed by the parties in December 2001.

Exhibit #	Document
1	United Kingdom Trademark Reg. No. 2290042 for RESTORADERM, filed January 14, 2002
2	European Union Trademark Reg. No. 002537074 for RESTORADERM, filed January 14, 2002
3	Switzerland Trademark Reg. No. 498975 for RESTORADERM, filed January 15, 2002, along with a copy of a certified translation thereof
4	Norway Trademark Reg. No. 216494 for RESTORADERM, filed January 15, 2002, along with a copy of a certified translation thereof
5	Israel Trademark Reg. No. 154752 for RESTORADERM, filed January 24, 2002, which includes a parallel certified translation thereof


- B. Pursuant to TBMP § 704.08, Registrant hereby introduces into evidence as Exhibit 6 a Press Release from Business Wire, published on February 12, 2002, entitled "CollaGenex Licenses Novel Dermal Delivery Platform." This document is relevant to the parties' respective priority dates in that it reflects that Registrant's predecessor-in-interest,

CollaGenex, issued a press release on February 12, 2002 announcing its product development efforts relating to RESTORADERM.

- C. Pursuant to TBMP § 704.10, Registrant hereby introduces into evidence, as Exhibit 7 – 10, portions of Petitioner’s Interrogatory Answers and Admissions.

Exhibit #	Document
7	Portions of Petitioner’s Responses to Registrant’s First Request for Admissions, served by Petitioner on Registrant on January 30, 2012
8	Portions of Petitioner’s Responses to Registrant’s Second Request for Admissions, served by Petitioner on Registrant on January 2, 2013
9	Portions of Petitioner’s Responses to Registrant’s First Set of Interrogatories, served by Petitioner on Registrant on January 30, 2012
10	Portions of Petitioner’s Responses to Registrant’s Second Set of Interrogatories, served by Petitioner on Registrant on January 2, 2013

Respectfully submitted,



Jeffrey M. Becker, Esq.
Lisa Normand Congleton, Esq.
Attorneys for Registrant
HAYNES AND BOONE, LLP
2323 Victory Avenue, Suite 700
Dallas, Texas 75219
Telephone: 214-651-5262
Facsimile: 214-200-0765
lisa.congleton@haynesboone.com

Date: March 31, 2014

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 1

United Kingdom Trademark Reg. No. 2290042 for RESTORADERM, filed January 14, 2002.



Intellectual
Property
Office

Certified Copy

I certify that the attached is a true copy of the entry of a trade mark in the United Kingdom register of trade marks.

John Alty

John Alty
Comptroller General of Patents, Designs and Trade Marks
Intellectual Property Office

Dated: 25 March 2014



Mark:
RESTORADERM

Trade Mark No: UK00002290042

Mark type: Word mark

Trade Mark status: Registered,OPEN

Trade Mark type: Standard

Filing Date: 14/01/2002 **Registration Date:** 21/06/2002

Renewal Date: 14/01/2022

Journal First Advert
Journal Number:6420
Publication Date: 06/03/2002

Goods and Services List:

Class 5:

Pharmaceutical, medicinal and veterinary preparations and substances.

Owner(s) Details:

Galderma S.A.

Zugerstrasse 8, 6330 Cham, Switzerland SWITZERLAND

Representatives Details:

A.A. Thornton & Co.

235 High Holborn WC1V 7LE London UNITED KINGDOM

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 2

European Union Trademark Reg. No. 002537074 for RESTORADERM, filed January 14, 2002.



Alicante, 30/01/2006

GREAVES BREWSTER LLP
Indigo House, Cheddar Business Park
Wedmore Road
Cheddar, Somerset BS27 3EB
REINO UNIDO

Certificate of Registration¹

Registration No.: 002537074
Your reference: RGM/T34327EM
Trade Mark: RESTORADERM
Applicant: CollaGenex International Limited
The Old Stable Block, 7 Buttermarket
Thame, Oxfordshire OX9 3EW
REINO UNIDO

Please find enclosed the certificate of registration for Community Trade Mark No. 002537074 which was published in the Community Trade Marks Bulletin no. 2006/005 on 30/01/2006 (see OHIM's website: <http://oami.europa.eu>).

This certificate contains information from the Community Trade Marks Register at the date of registration (see code 151 on the certificate). If you have filed a request for modification of data on or after that date, no new certificate will be issued. You will be notified separately of the change after which an extract from our database may be requested to reflect the administrative status of the mark.

For an explanation of the codes on the certificate please consult the Vademecum on OHIM's website: <http://oami.europa.eu/pdf/mark/vademecum-ctm-en.pdf>.

If you do not agree with the content of this certificate please do not send back the original. You should instead send the Office a letter indicating your objections, which will be dealt with separately.

Catherine DOBSON

¹in accordance with Rule 24(1) of Commission Regulation (EC) No 2868/95 of 13 December 1995 implementing Council Regulation (EC) No 40/94 on the Community trade mark (<http://oami/en/mark/aspects/reg/reg2868.htm>) ("Community Trade Mark Implementing Regulation" or "CTMIR") (<http://oami.europa.eu>)



Registered / Enregistré 24/11/2005

No 002537074

**OHIM – OFFICE FOR HARMONIZATION IN THE
INTERNAL MARKET
TRADE MARKS AND DESIGNS**

CERTIFICATE OF REGISTRATION

This Certificate of Registration is hereby issued for the Community Trade Mark identified below. The corresponding entries have been recorded in the Register of Community Trade Marks.

**OHMI – OFFICE DE L'HARMONISATION DANS LE
MARCHÉ INTÉRIEUR
MARQUES, DESSINS ET MODÈLES**

CERTIFICAT D'ENREGISTREMENT

Le présent Certificat d'Enregistrement est délivré pour la marque communautaire identifiée ci-joint. Les mentions et les renseignements qui s'y rapportent ont été inscrits au Registre des Marques Communautaires.

RESTORADERM

The President / Le Président

Wubbo de Boer



- 210 002537074
220 14/01/2002
400 02/12/2002
151 24/11/2005
450 30/01/2006
186 14/01/2012
541 RESTORADERM
732 CollaGenex International Limited
The Old Stable Block
7 Buttermarket
Thame, OX9 3EW
GB
740 GREAVES BREWSTER LLP
Indigo House, Cheddar Business Park Wedmore Road
Cheddar, BS27 3EB
GB
270 EN FR
511 **ES** - 5
Preparaciones y sustancias farmacéuticas, médicas y veterinarias, excluyendo preparaciones de hormonas.
DA - 5
Farmaceutiske, medicinske og veterinærmedicinske præparater og stoffer, eksklusive hormonpræparater.
DE - 5
Pharmazeutische, medizinische und veterinärmedizinische Erzeugnisse und Substanzen, ausgenommen Hormonpräparate.
EL - 5
Φαρμακευτικά, ιατρικά και κτηνιατρικά παρασκευάσματα και ουσίες εκτός από ορμονικά παρασκευάσματα.
EN - 5
Pharmaceutical, medical and veterinary preparations and substances excluding hormone preparations.
FR - 5
Produits et substances pharmaceutiques, médicaux et vétérinaires, à l'exception des produits hormonaux.
IT - 5
Prodotti e sostanze farmaceutici, medici e veterinari, tranne i preparati ormonali.
NL - 5
Farmaceutische, medische en diergeneeskundige producten en substanties, met uitzondering van hormonenpreparaten.
PT - 5
Produtos e substâncias farmacêuticos, médicos e veterinários, com exceção de produtos hormonais.
FI - 5
Farmaseuttiset, lääkintä- ja eläinlääkintätuotteet ja -aineet, paitsi hormonivalmisteet.
SV - 5
Farmaceutiska, medicinska och veterinära preparat och substanser, ej hormonpreparat.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 3

**Switzerland Trademark Reg. No. 498975 for RESTORADERM, filed January 15, 2002, along with
a copy of a certified translation thereof.**

Attestation d'enregistrement de la marque

L'Institut Fédéral de la Propriété Intellectuelle confirme les indications suivantes qui ont été inscrites au registre des marques suisse.

No d'enregistrement : P-498975
Demande d'enregistrement : 00324/2002
Date de dépôt / début de la protection : 15 janvier 2002
Echéance de la protection : 15 janvier 2022
Première publication dans : FOSC no 100
Première publication le : 28 mai 2002

RESTORADERM

Titulaire

CollaGenex International Limited
(A British limited company)
The Old Stable Block,
7, Buttermarket
Thame (Oxon OX9 3EW)
GB-Royaume-Uni

Mandataire

Jacobacci & Partners S.A.
2, avenue de la Gare des Eaux-Vives
1207 Genève

Liste des produits et/ou des services

5

Préparations et substances pharmaceutiques, médicinales et vétérinaires.

Classification internationale

5

Enregistrement dans le registre des marques

14.05.2002

Division des marques
Brigitte Bolli







TRANSPERFECT


AFFIDAVIT OF ACCURACY

I, Shawdi Rahbar, hereby certify that the document listed below are, to the best of my knowledge and belief, a true and accurate translation of the document "CH P-498975 RESTORADERM_Registration certificate (ID 136786).pdf" from French to English (US).


Shawdi Rahbar

Sworn to before me this
24th day of March 2014


Signature, Notary Public



Stamp, Notary Public



Eidgenössisches Institut für Geistiges Eigentum
Institut Fédéral de la Propriété Intellectuelle
Istituto Federale della Proprietà Intellettuale
Swiss Federal Institute of Intellectual Property

Stauffacherstrasse 65/59g | CH-3003 Bern
T +41 31 377 77 77
F +41 31 377 77 78
info@ipi.ch | www.ige.ch

Certificate of trademark registration

The Federal Institute of Intellectual Property hereby confirms that the following information has been recorded in the Swiss Trademark Register.

Registration No.	: P-498975
Trademark registration application	: 00324/2002
Filing date / start of protection	: January 15, 2002
Expiration of protection	: January 15, 2022
First published in	: FOSC No. 100
First published on	: May 28, 2002

RESTORADERM

Trademark Holder

CollaGenex International Limited
(A British limited company)
The Old Stable Block,
7, Buttermarket
Thame (Oxon OX9 3EW)
GB – United Kingdom

Attorney

Jacobacci & Partners S.A.
2, avenue de la Gare des Eaux-Vives
1207 Geneva

List of products and/or services

5

Pharmaceutical, medicinal and veterinary preparations and substances

International classification

5

Registered in the trademark register

05/14/2002



Eidgenössisches Institut für Geistiges Eigentum
Institut Fédéral de la Propriété Intellectuelle
Istituto Federale della Proprietà Intellettuale
Swiss Federal Institute of Intellectual Property

Stauffacherstrasse 65/59g | CH-3003 Bern
T +41 31 377 77 77
F +41 31 377 77 78
info@ipi.ch | www.ige.ch

Trademark Division
Brigitte Bolli

[round stamp:]
Federal Institute of Intellectual Property

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 4

Norway Trademark Reg. No. 216494 for RESTORADERM, filed January 15, 2002, along with a copy of a certified translation thereof.



KONGERIKET NORGE
The Kingdom of Norway

Bekreftelse på varemerke reg nr
Certification of trademark reg no

216494

▶ Det bekreftes herved at vedheftede dokument er nøyaktig utskrift/kopi av ovennevnte registrering

▶ *It is hereby certified that the annexed document is a true copy of the above-mentioned registration*

2014.03.25

Eli Edvardsen

Eli Edvardsen
Saksbehandler

REGISTRERTE OPPLYSNINGER – REGISTERED DATA

(111) **Reg.nr:** 216494
(151) **Reg.dato:** 2002.11.14
(300) **Prioritet:**
(210) **Søknadsnr:** 200200212
(220) **Inndato:** 2002.01.15
(180) **Registreringsperioden
utløper:** 2022.11.14
(540) **Gjengivelse av merket:**
RESTORADERM

(541) **Merketype:** Merket er et ordmerke i standard font



(730) **Innehaver:**
Galderma SA, Zugerstrasse 8, CH-6330 CHAM, Sveits
Søker:
CollaGenex International Ltd, The Old Stable Block, 7 Buttermarket, Thame, GB-
OX93EW OXFORDSHIRE , Storbritannia

(740) **Fullmektig:**
(750) Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(511) **Varer og/eller tjenester:**

Klasse 5 Farmasøytiske, medisinske og veterinære preparater og
substanser.



TRANSPERFECT


AFFIDAVIT OF ACCURACY

I, Artem Furman, hereby certify that the attached document is, to my knowledge and belief, a true and accurate translation of the file, "Certified copy RESTORADERM" from Norwegian into English.

Artem Furman
3 Park Ave
New York, NY 10016

Sworn before me on this
28th Day of March 2014

Signature, Notary Public



Stamp, Notary Public

March 25, 2014



Case manager

patents trademarks designs
The Norwegian Patent Office

REGISTERED DATA

- (111) **Reg. no.:** 216494
(151) **Reg. date:** November 14, 2002
(300) **Priority:**
(210) **Application no.:** 200200212
(220) **Date received:** January 15, 2002
(180) **Registration period expires:** November 14, 2022
(540) **Reproduction of the mark:**
RESTORADERM [Seal] Norwegian Patent Office
Norwegian Industrial Property Office
- (541) **Type of mark:** The mark is a word mark in standard font
- (730) **Holder:**
Galderma SA, Zugerstrasse 8, CH-6330 CHAM, Switzerland
Applicant:
CollaGenex International Ltd., The Old Stable Block, 7 Buttermarket, Thame, GB OX93EW
OXFORDSHIRE, Great Britain
- (740) **Representative:**
(750) Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norway
- (511) **Goods and/or services:**
Class 5: Pharmaceutical, medical and veterinarian preparations and substances.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 5

Israel Trademark Reg. No. 154752 for RESTORADERM, filed January 24, 2002, which includes a parallel certified translation thereof.



מדינת ישראל
STATE OF ISRAEL

Certificate under rule 84
the Trade Marks Rules, 1940

תעודה על פי תקנה 84
לתקנות סימני המסחר, 1940

מס' 154752 No.

THIS IS TO CERTIFY
that the annexed hereto is a
true copy of the trade/service
mark certificate as deposited.

זאת לתעודה כי
רצוף בזה העתק נכון של הנסח
לרישום סימן מסחר/שרות כפי
שהופקד.

היום כ"ג באדר ב תשע"ד
Today 25.03.2014

ענת לוי
מנהלת מחלקת סימני מסחר



154752

25/03/2014



נסח סימן מסחר
Trade Mark Extract



RESTORADERM

Trade Mark No.	154752	מספר סימן
Application Date	24/01/2002	תאריך הגשה
Expiration Date	24/01/2022	תאריך תום תוקף

Goods/Services

סחורות/שירותים

Class: 5

סוג: 5

Pharmaceutical, medicinal and veterinary preparations and substances, all for dermatological use or being for application to the skin; all included in class 5.

תכשירים וחומרים רוקחיים, רפואיים ווטרינריים, כולם לשימוש דרמטולוגי או להשמה על העור; הנכללים כולם בסוג 5.

TRUE COPY


 Jerusalem.....
 for Registrar of Trade Marke

Owners

Name: Galderma S.A.

Address: Zugerstrasse 8, Cham, CH-6330, Switzerland

Address for service

Name: Reinhold Cohn and Partners

Address: 26a Habarzel St. Ramat Hahayal, P.O.B.
13239, Tel Aviv, 61131, Israel

המען למסירת הודעות

שם: ריינהולד כהן ושותפיו

כתובת: רחוב הברזל 26 א', רמת החייל, ת.ד. 13239, תל
אביב, 61131, ישראל

Changes

יומן שינויים

תאריך הפרסום	תאור (לועזית)	תאור (עברית)	מהות הארוע (לועזית)	מהות הארוע (עברית)	תאריך הארוע
Publication date	Description (English)	Description (Hebrew)	Nature of event (English)	Nature of event (Hebrew)	Date of event
			Accepted	קובל	10/11/2004
01/2005			Accepted	קובל	31/01/2005
06/2005			Registered	רישום	08/05/2005
01/2008	CollaGenex International Limited		Change in ownership from	העברת בעלות מ	17/10/2007
	Reinhold Cohn and Partners	ריינהולד כהן ושותפיו	Appointment of attorney	מינוי מיופה כוח	03/07/2011
	CollaGenex Pharmaceuticals, Inc.		Change in ownership from	העברת בעלות מ	03/07/2011
	Eitan Mehulal Law Group	איתן, מהולל, פאפו, קוגלר	Cancellation of attorney appointment	ביטול מיופה כוח	03/07/2011
	Galderma Laboratories, Inc.		Change in ownership from	העברת בעלות מ	03/07/2011
31/07/2011	Galderma Pharma S.A.		Change in ownership from	העברת בעלות מ	03/07/2011
29/12/2011			Renewal of registration	חידוש התוקף	19/12/2011



TRUE COPY

Jerusalem.....
for Registrar of Trade Marke

מספר מיופה : 1

סימוכין : 2085420

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 6

Press Release from Business Wire, Dated February 12, 2002

- Source : Press Release
- Date : 2002-02-12
- Companies : CollaGenex Pharmaceuticals Inc.

CollaGenex Licenses Novel Dermal Drug Delivery Platform

NEWTOWN, Pa., Feb 12, 2002 (BUSINESS WIRE) -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it has licensed a novel dermal and transdermal drug delivery technology from its inventor.

The technology, named Restoraderm(TM), is designed to enhance the dermal delivery of a variety of active ingredients and will form the basis for a novel, proprietary and differentiated portfolio of topical dermatological pharmaceuticals.

The technology is based on the ability of certain lipid compositions to enhance the natural skin barrier and facilitate the dermal and transdermal delivery of known active ingredients. The Restoraderm technology is currently still under development, and CollaGenex anticipates that the first products to be developed using the technology will be available in late 2002.

In exchange for the rights to the technology, CollaGenex will pay the inventor milestone fees upon the achievement of certain objectives as well as royalties on future sales of products based on the technology.

"The licensing of the Restoraderm drug delivery technology is an important element of our strategy to build a diversified portfolio of products for the dermatology market," noted Brian M. Gallagher, PhD, chairman, president and chief executive officer of CollaGenex. "We anticipate that our future business in dermatology will include three key elements. Our first sales in this area will come from established, under-promoted products that we in-license, and we expect to complete the first of these agreements in the near future. The second key business element will be composed of dermatology products based on the Restoraderm technology, the first of which we hope to launch later this year. Finally, and perhaps most importantly, will be the development of the clinical use of Periostat to treat acne and rosacea, for which we plan a series of clinical trials during 2002 and 2003."

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on providing innovative medical therapies to the dental and dermatology market. The Company's lead product, Periostat, is the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues.

Periostat is marketed to the dental community through a professional pharmaceutical sales force composed of approximately 120 sales representatives and managers.

Currently, the Company's dental sales force is also marketing Vioxx(R), a Merck & Co. drug that CollaGenex co-promotes for the treatment of acute dental pain, and Atridox(R), Atrisorb(R) and Atrisorb-D(R), Atrix Laboratories Inc.'s products for the treatment of adult periodontitis.

Research has shown that the enzyme suppression technology underlying Periostat may also be applicable to other diseases involving destruction of the body's connective tissues, including cancer metastases (Metastat) and a broad range of inflammatory diseases.

CollaGenex is developing a series of novel, proprietary compounds known as IMPACS (Inhibitors of Multiple Proteases and CytokineS) to address these applications. The Company intends to pursue further research and development of these technologies primarily through partnerships with third parties.

To receive additional information on the Company, please visit our Web site at www.collagenex.com, which is not a part of this press release.

This news release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Investors are cautioned that forward-looking statements involve risks and uncertainties, which may affect the Company's business and prospects.

The Company's business of selling, marketing and developing pharmaceutical products is subject to a number of significant risks, including risks relating to the implementation of the Company's sales and marketing plans for Periostat; risks inherent in research and development activities; risks associated with conducting business in a highly regulated environment and uncertainty relating to clinical trials of products under development, all as discussed in the Company's periodic filings with the US Securities and Exchange Commission.

Periostat(R), Metastat(R) and IMPACS(R) are trademarks of CollaGenex Pharmaceuticals, Inc.

VIOXX(R) is a trademark of Merck & Co., Inc.

Atridox(R), Atrisorb(R) and Atrisorb-D(R) are trademarks of Atrix Laboratories, Inc.

Periostat(R) and CollaGenex(R) are trademarks of CollaGenex International Limited.

CONTACT: CollaGenex Pharmaceuticals, Inc.
Robert A. Ashley, 215/579-7388

URL: <http://www.businesswire.com>
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 7

**Portions of Petitioner's Responses to Registrant's First Request for Admissions, Served by
Petitioner on Registrant on January 30, 2012.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Registration Nos. 2985751; and 3394514

Dated: August 16, 2005 & March 11, 2008, Respectively

Thomas Sköld,)	
Petitioner,)	
)	
v.)	
)	Cancellation No. 92052897
Galderma Laboratories, Inc.,)	
Registrant)	
_____)	

BOX TTAB/FEE
Commissioner for Trademarks
2900 Crystal Drive
Arlington, VA 22202-3513

**PETITIONER SKÖLD'S RESPONSE TO REGISTRANT'S FIRST REQUESTS FOR
ADMISSIONS**

Pursuant to Rules 26 and 36 of the Federal Rules of Civil Procedure, Petitioner Thomas Sköld ("Sköld"), by and through its undersigned counsel, submits this response to the Registrant's First Requests for Admissions as follows set forth below.

The statement that "Petitioner denies/admits this assertion" or equivalent language signifies that Petitioner denies/confirms the Request for Admission immediately preceding the language.

Request for Admission 10:

The goods listed in the two U.S. trademark applications referenced in Request for Admission 9 are both for a lipid structural matrix, one of which is intended to be sold as a component of dermatological preparations and the other as a component of a pharmaceutical preparation.

Petitioner admits this assertion.

Request for Admission 14:

Petitioner did not sell goods prior to February 11, 2002 that bore the RESTORADERM mark in any manner.

Petitioner denies this assertion in that: Petitioner made bona fide efforts to sell goods that bore the RESTORADERM mark prior to this date, and goods that bore the RESTORADERM mark were transferred to at least one commercially motivated party prior to February 11, 2002. Petitioner acknowledges that there was not transfer of consideration to Sköld in exchange for the goods prior to February 11, 2002, nor a memorialized agreement for consideration prior to this date.

Request for Admission 16:

Petitioner did not sell goods prior to February 11, 2002 in containers bearing the RESTORADERM mark.

Petitioner denies this assertion in that: Petitioner made bona fide efforts to sell goods that bore the RESTORADERM mark prior to this date, and containers of goods that bore the RESTORADERM mark were transferred from him to at least one commercially motivated party prior to February 11, 2002. Petitioner acknowledges that there was not transfer of consideration to Sköld in exchange for the goods prior to February 11, 2002, nor a memorialized agreement for consideration prior to this date.

Request for Admission 49:


Petitioner was aware of Registrant's filing of either or both of the U.S. trademark applications for RESTORADERM, which applications matured into U.S. Trademark Registration Nos. 3,394,514 and 2,985,751, upon the date of the filing of such applications.

Petitioner was aware of the filing that matured to U.S. Trademark Registration No. 2,985,751 in the relative time frame of the date of filing, though he cannot recall if he was aware of the filing on the date of the filing. Petitioner cannot confirm or deny whether he knew of the filing for the '751 registration on the date of that filing. Petitioner denies any other aspect of this Request for Admission.

VERIFICATION

Thomas Sköld, acknowledging that this verification is made under penalty of perjury, states that he has read the foregoing Petitioner Sköld's Response to Registrant's First Requests for Admissions, and that to the best of his knowledge, information and belief, the facts set forth therein are true and correct.

DATED: March 15, 2012



Thomas Sköld

Respectfully submitted,

Date: March 15, 2012

By:

A handwritten signature in black ink, appearing to read "A. E. Jackson", written over a horizontal line.

Arthur E. Jackson, Ph.D., Esq.
New Jersey Bar No. 00288-1995
ajackson@moseriplaw.com
MOSER IP LAW GROUP
1030 Broad Street, Suite 203
Shrewsbury, NJ 07702
(732) 935-7100
(732) 935-7122
Attorney for Petitioner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Thomas Sköld,
Petitioner,

v.


Galderma Laboratories, Inc.,
Registrant

)
)
)
)
) Cancellation No. 92052897
)
)
)

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Petitioner Sköld's Response to Registrant's First Request for Admissions was sent by email on this 15th of March, 2012 to:

Jeff.Becker@haynesboone.com



Arthur E. Jackson

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 8

**Portions of Petitioner's Responses to Registrant's Second Request for Admissions, served by
Petitioner on Registrant on January 2, 2013.**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

REGISTRANT'S SECOND REQUEST FOR ADMISSIONS

Pursuant to Rules 37 C.F.R. §§ 2.116(a) and 2.120, Fed. R. Civ. P. 26 and 36, and TBMP §§ 403.02 and 408.01, Registrant Galderma Laboratories, Inc. herewith requests that Petitioner Thomas Sköld admit the truth of the following numbered statements. As directed by Fed. R. Civ. P. 36, Petitioner shall file a written response to this Second Request for Admissions within thirty (30) days after the date of service. Petitioner shall send the requested responses to Jeffrey M. Becker, Haynes and Boone, LLP, at jeff.becker@haynesboone.com. Each request for admission shall be deemed continuing in nature, and Petitioner shall update, revise, and otherwise keep current any information provided in response to each request as facts or circumstances become known or change, in accordance with Fed. R. Civ. P. 26(e).

DEFINITIONS

The following definitions apply to, and are deemed to be incorporated into, each of the requests herein.

A. "Allergan" means Allergan, Inc. and its present and former divisions, subdivisions, affiliates, parents, and subsidiary entities, predecessors in interest or title, successors, and any and all related companies (as defined by 15 U.S.C. § 1127), as well as all persons acting or purporting to act on behalf of any of such entities.

B. "CollaGenex" means Registrant's predecessor in interest, CollaGenex Pharmaceuticals, Inc.

L. “Petitioner’s Document No. 102” means the single-page document that: (i) Petitioner produced in response to Registrant’s First Request for Production of Documents and Things; (ii) bears the heading caption “A theory of the ‘mode of action’ concerning this new technology”; (iii) bears the date “5 November, 2001”; and (iv) is attached to this Second Request for Admissions as Exhibit “A.”

M. “Petitioner’s Document No. 103” means the single-page document that: (i) Petitioner produced in response to Registrant’s First Request for Production of Documents and Things; (ii) bears the heading caption “LipoDerm Restoraderm a vehicle technology for topical use”; and (iii) is attached to this Second Request for Admissions as Exhibit “B.”

N. “Registrant” means Galderma Laboratories, Inc., and its present and former divisions, subdivisions, affiliates, parents, and subsidiary entities, predecessors in interest or title, successors, and any and all related companies (as defined by 15 U.S.C. § 1127), as well as all persons acting or purporting to act on behalf of any of such entities.

O. “Relating to” means relating to, reflecting, supporting, evidencing, discussing, showing, summarizing, analyzing, containing, pertaining to, or concerning in any way, directly or indirectly.

P. “Technology” means the technology utilizing phospholipid or ceramide, cholesterol, and fatty acid for dermally and transdermally delivering bioactive substances, as discussed in the Amended Petition for Cancellation.

Q. “U.S.” means the United States of America.

INSTRUCTIONS

Petitioner is hereby advised that a failure to specifically deny any request will be taken as an admission of the truth of the request.

Thomas Sköld v. Galderma Laboratories, Inc.
Cancellation No. 92052897

EXHIBIT A

A theory of the "mode of action" concerning this new technology
5 November, 2001

The vehicle is designed in its choice of and share of lipids to resemble the normal lipid organisation of the stratum corneum. Thus the administered vehicle will easily penetrate the lipid bilayer of the skin and in doing so create a temporary and reversible state of enhanced atrophy among the bilayer.

The enhanced atrophy in itself should then give rise to a) enhanced energy levels, said energy could promote active transport of the to-be-carried substances into the skin, and/or b) naturally and reversibly occurring holes and disorganised patches in the lipid bilayer, through which the active substances could then pass more easily.

It is very well feasible that the temporary disarray in the lipid bilayer will temporarily break up the organised structure of the bilayer and create micelles of lipids with areas between them/ surrounding them through which lipophobic/hydrophilic substances and compositions can enter the stratum corneum.

As the content of the vehicle resembles the natural lipid build-up of the skin, the so introduced new lipids will after a short span of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer and thus not permanently damage the skin.

Thomas Sköld

LipoDerm Lipoid Restoraderm Technology

Thomas Sköld v. Galderma Laboratories, Inc.
Cancellation No. 92052897

EXHIBIT B

CONFIDENTIAL

LipoDerm Restoraderm a vehicle technology for topical use

This technology is a water based lipid product aimed to deliver, to the human body and skin, different active ingredients with a therapeutic value. The lipids that are used are very similar or the same as what is natural existing in the stratum corneum (skin barrier) with an exception of triglycerides, namely palmitin acid, cholesterol and ceramide 3. To this lipids also mevalonic acid is added, a substance that contributes to the lipid biosynthesis. It takes a very small portion of mevalonic acid, in time, to reach the same cholesterol level as if cholesterol is delivered direct to the skin. The lipid content in this technology is only 6-13% and the water content 70-80%, which allows the skin to breath (evaporate) normally. Some active ingredient needs to be dissolved in for example propylene glycol or ethanol and in those cases that amount should be taken out from the water content.

Vehicles has until recently not been given to much credit and products has been developed on either an alcohol or petrolatum base depending on the solubility on the active ingredient. In the treatment of a skin disorder the vehicle can act both positive and negative to the skin. This technology is developed to act as a part of the treatment regime, which means that at the same time as it is delivering the active ingredient it is also restoring the skin barrier function. It is doing that through delivering natural lipids but also, with the lipid biosynthesis, in time help the skin to produce some of them it self.

It is important not to change, too much, the structure and functioning of these lipids. An emulsified fatty acid for an example will not keep its lipid abilities. On the contrary it will act as a detergent instead, which means ability to disrupt the barrier. When formulating, this fact needs to be considered.

For an active ingredient to penetrate the stratum corneum it some time needs help by a "penetration enhancer", which is a substance that will breake the natural lipid pattern and resistance. With chronic use of such a substance one will disrupt the barrier function and the "transepidermal water loss" (TEWL) will increase, which will result in a sensitive skin followed by a skin disorder.

The theory behind this technology is, when the vehicles lipids blends with the lipids of the stratum corneum a very temporarily disorder will occur and the active ingredient can during that time more easily penetrate. This can be explained in more technical terms but future studies can give a more thoroughly explanation/description of what is happening.

Studies that should be done in the nearest 8-12 month are;

- 1, Lipid study tape stripping human skin measuring lipid contents after applications
- 2, Blanching study measuring potency of a hydrocortisone in different vehicles
- 3, Dual action study the effect of the vehicles in chronic hand dermatitis
- 4 Surface anastatical study a comparesant study with other formulations

Request for Admission 204:

Prior to February 28, 2002, Petitioner did not have an advertising budget for promoting any service that in any way bore the mark RESTORADERM to consumers in the U.S.

Request for Admission 205:

Prior to February 28, 2002, Petitioner did not purchase any advertisement time to promote any service that in any way incorporated the Technology to consumers in the U.S.

Request for Admission 206:

Prior to February 28, 2002, Petitioner did not have an advertising budget for promoting any service that in any way incorporated the Technology to consumers in the U.S.

Request for Admission 207:


Prior to February 28, 2002, Petitioner's use of the mark RESTORADERM in the U.S. was not sufficient to inform or apprise prospective purchasers of the present availability of Petitioner's services under the mark RESTORADERM.

Request for Admission 208:

Prior to February 28, 2002, Petitioner's use of the mark RESTORADERM in the U.S. was not sufficient to inform or apprise prospective purchasers of the future availability of Petitioner's services under the mark RESTORADERM.

Date: January 2, 2013

Respectfully submitted,



Jeffrey M. Becker, Esq.

Lisa N. Congleton, Esq.

Attorneys for Registrant

HAYNES AND BOONE, LLP

2323 Victory Avenue, Suite 700

Dallas, Texas 75219

Telephone: 214-651-5262

Facsimile: 214-200-0765

jeff.becker@haynesboone.com

lisa.congleton@haynesboone.com

The statement that "Petitioner denies/admits this assertion" or equivalent language signifies that Petitioner denies/confirms the Request for Admission immediately preceding the language.

Request for Admission 52:

All of the documents that Petitioner produced in response to Registrant's First Request for Production of Documents and Things are true and correct copies of authentic documents.

On information and belief, all documents he has produced are true and correct copies of authentic documents.

Request for Admission 53:

All of the documents that Petitioner produced in connection with his Initial Disclosure under Rule 26(a)(1)(A)(ii), as listed under "Part A" and "Part C" of Petitioner's counsel's January 17, 2012 letter to Registrant's counsel, are true and correct copies of authentic documents.

On information and belief, all documents he has produced are true and correct copies of authentic documents.

Request for Admission 54:

All of the documents that Petitioner produced in connection with his First Updated Initial Disclosure under Rule 26(a)(1)(A)(ii), as listed under "Part A" of Petitioner's counsel's March 15, 2012 letter to Registrant's counsel, are true and correct copies of authentic documents.

Petitioner objects to this Request as duplicative of Request 53.

Request for Admission 56:

Petitioner's Document No. 102 is the document Petitioner refers to as the "Mode of Action Document" in his responses to Registrant's Interrogatories numbers 4 and 6.

Petitioner confirms the assertion.

Request for Admission 68:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 in the U.S. in any catalog.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 69:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 in the U.S. in any newspaper.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 70:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 in the U.S. in any magazine.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 71:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 in the U.S. in any press release.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 72:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 in the U.S. in any trade publication.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 75:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 102 in the U.S. in any catalog.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 76:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 102 in the U.S. in any newspaper.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 77:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 102 in the U.S. in any magazine.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 78:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 102 in the U.S. in any press release.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 79:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 102 in the U.S. in any trade publication.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 89:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 in the U.S. in any catalog.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 90:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 in the U.S. in any newspaper.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 91:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 in the U.S. in any magazine.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 92:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 in the U.S. in any press release.

Petitioner objects to this Request as unduly burdensome. It has been clear from the

papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 93:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 in the U.S. in any trade publication.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 96:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 103 in the U.S. in any catalog.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 97:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 103 in the U.S. in any newspaper.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 98:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 103 in the U.S. in any magazine.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 99:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 103 in the U.S. in any press release.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 100:

Prior to February 28, 2002, Petitioner did not present the information contained in Petitioner's Document No. 103 in the U.S. in any trade publication.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use, at the time, of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 109:

Prior to February 28, 2002, Petitioner did not deliver any substance in a container that in any way bore the mark RESTORADERM to Medicis.

Petitioner confirms this assertion.

Request for Admission 116:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 to Ortho-McNeil.

Petitioner confirms this assertion.

Request for Admission 117:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 to Ortho-McNeil.

Petitioner confirms this assertion.

Request for Admission 119:

Prior to February 28, 2002, Petitioner did not meet with Allergan regarding the Technology.

Petitioner confirms this assertion.

Request for Admission 120:

Petitioner did not meet with Allergan on September 11, 2001.

Petitioner confirms this assertion.

Request for Admission 122:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 102 to Allergan.

Petitioner confirms this assertion.

Request for Admission 123:

Prior to February 28, 2002, Petitioner did not present Petitioner's Document No. 103 to Allergan.

Petitioner confirms this assertion.

Request for Admission 164:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 166:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any newspaper advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any newspaper advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 167:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any magazine article in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any magazine article in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 168:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any magazine advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any magazine article in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 169:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any catalog in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any catalog in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 170:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any trade publication in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any trade publication in the U.S. in a manner in a manner sponsored by or otherwise directly

affiliated with Petitioner.

Request for Admission 171:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any television advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any television advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 172:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any billboard advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any billboard advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 173:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any broadcast or satellite radio advertisement in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any broadcast or satellite radio advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 174:

Prior to February 28, 2002, the mark RESTORADERM did not appear in any drug-product informational pamphlet in the U.S.

Prior to February 28, 2002, the mark RESTORADERM did not appear in any drug-product informational pamphlet in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 177:

Prior to February 28, 2002, no information relating to the Technology appeared in any advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 178:

Prior to February 28, 2002, no information relating to the Technology appeared in any newspaper article in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any newspaper article in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 179:

Prior to February 28, 2002, no information relating to the Technology appeared in any newspaper advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any

newspaper advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 180:

Prior to February 28, 2002, no information relating to the Technology appeared in any magazine article in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any magazine article in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 181:

Prior to February 28, 2002, no information relating to the Technology appeared in any magazine advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any magazine advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 182:

Prior to February 28, 2002, no information relating to the Technology appeared in any catalog in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any catalog in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 183:

Prior to February 28, 2002, no information relating to the Technology appeared in any trade publication in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any trade publication in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 184:

Prior to February 28, 2002, no information relating to the Technology appeared in any television advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any television advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 185:

Prior to February 28, 2002, no information relating to the Technology appeared in any billboard advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any billboard advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 186:

Prior to February 28, 2002, no information relating to the Technology appeared in any broadcast or satellite radio advertisement in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any broadcast or satellite radio advertisement in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 187:

Prior to February 28, 2002, no information relating to the Technology appeared in any drug-product informational pamphlet in the U.S.

Prior to February 28, 2002, no information relating to the Technology appeared in any drug-product informational pamphlet in the U.S. in a manner sponsored by or otherwise directly affiliated with Petitioner.

Request for Admission 203:

Prior to February 28, 2002, Petitioner did not purchase any advertisement time to promote any service that in any way bore the mark RESTORADERM to consumers in the U.S.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use of the mark. Subject to this objection, Petitioner confirms the assertion.

Request for Admission 205:


Prior to February 28, 2002, Petitioner did not purchase any advertisement time to promote any service that in any way incorporated the Technology to consumers in the U.S.

Petitioner objects to this Request as unduly burdensome. It has been clear from the papers Petitioner filed with the Board and served to the Registrant that this form of advertising is not germane to his use of the mark. Subject to this objection, Petitioner confirms the assertion.

VERIFICATION

Thomas Sköld, acknowledging that this verification is made under penalty of perjury, states that he has read the foregoing Petitioner Sköld's Response to Registrant's Second Requests for Admissions, and that to the best of his knowledge, information and belief, the facts set forth therein are true and correct.

DATED: February 6, 2013



Thomas Sköld

Respectfully submitted,

Date: February 7, 2013

By: / Arthur E. Jackson /

Arthur E. Jackson, Ph.D., Esq.
New Jersey Bar No. 00288-1995
ajackson@moseriplaw.com
MOSER IP LAW GROUP
1030 Broad Street, Suite 203
Shrewsbury, NJ 07702
(732) 935-7100
(732) 935-7122
Attorney for Petitioner


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Thomas Sköld, Petitioner,)	
)	
v.)	
)	Cancellation No. 92052897
Galderma Laboratories, Inc., Registrant)	

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Petitioner Sköld's Response to Registrant's **Second Request for Admissions** was sent by email on this 7th of February, 2013 to:

Jeff.Becker@haynesboone.com



Arthur E. Jackson

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 9

**Portions of Petitioner's Responses to Registrant's First Set of Interrogatories, served by Petitioner
on Registrant on January 30, 2012.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Registration Nos. 2985751; and 3394514

Dated: August 16, 2005 & March 11, 2008, Respectively

Thomas Sköld,)	
Petitioner,)	
)	
v.)	
)	Cancellation No. 92052897
Galderma Laboratories, Inc.,)	
Registrant)	
)	

PETITIONER SKÖLD'S RESPONSE TO REGISTRANT'S FIRST SET OF INTERROGATORIES

Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure, Petitioner Thomas Sköld ("Sköld"), by and through its undersigned counsel, submits this response to the Registrant's First Set of Interrogatories as set forth below.

As a general note, applicable to multiple Interrogatories, Petitioner's RESTORADERM Technology is based on (a) compositions of stratum corneum lipids (phospholipids/ceramide/cholesterol/fatty acid), and (b) the presence of different macromolecular aggregates formed of the lipids. Its primary intent is for formulation for delivering pharmaceutically active substances into or through the dermis of a patient. But Sköld's use of the trademark has extended to the vehicle. References herein to the "RESTORADERM Technology" are references to technology encompassing (a) and (b).

As a general note, the responses below may speak of "Registrant," where the context should make clear whether the referenced party was, at the time of events recited, Galderma Laboratories, Inc. ("Galderma") or its predecessor in interest, Collagenex Pharmaceuticals, Inc. ("Collagenex"). At other times, the specific such party may be called out.

Interrogatory No.4:

Describe in detail how the term RESTORADERM was first conceived of.

Response to Interrogatory No. 4:

At an early stage of development Sköld and Mats Silvander were brainstorming about giving the development a name and came up with Lipoid, LipoDerm, Restoraderm for use with various aspects of technology under consideration. The idea was to use Restoraderm for topical delivery and Lipoid for nasal/oral delivery. Lately the nasal and oral system goes under the trademark LipoGrid Technology.

The topical technology labeled with the Lipoderm and RESTORADERM marks was presented to Collagenex on Sept 11th 2001, especially via a document substantially identical to that labeled "A theory of the "mode of action" concerning this new technology" ("Mode of Action Document"). In early 2002 Collagenex had a couple of sessions internally (Jeff Day, Rob Ashley and Chris Powala) to decide which the Sköld's trademarks they were comfortable with and settled on Restoraderm. Collagenex then asked if Sköld was fine with that choice, and he gave them approval (contingent on the license), which led to the license provided by the 2002 Agreement. Since then the mark has been associated with RESTORADERM Technology, though since 2010 there has been the confusion brought on by Registrant's unlicensed and misleading use of the mark.

The Mode of Action Document is being provided with the First Updated Initial Disclosures.

Interrogatory No.6:

State the date of, and describe in detail the circumstances of, your first use of the mark RESTORADERM in commerce in connection with the sale, offering for sale, distribution, or advertising of a dermatology product.

Response to Interrogatory No. 6:

The week of Sept. 11, 2001, Sköld had scheduled meetings with Neutrogena (Ortho McNeil), Medicis and Alerga, each of which had received from Sköld the Mode of Action Document. Each of these was a set up as part of selling RESTORADERM Technology product and services.

In late 2001, prior to any usage or conception of usage by Registrant, Petitioner delivered to Collagenex RESTORADERM labeled samples of a base formulation for RESTORADERM Technology.

Petitioner's meeting with Collagenex is set forth in the answer to Interrogatory No. 4.

Moreover, in November or December of 2001, samples labeled "RESTORADERM Technology" were delivered to Collagenex.

Interrogatory No. 24:

Explain why Petitioner entered into the 2002 Agreement.

Response to Interrogatory No. 24:

In September 2001 Sköld traveled to the United States for a number of meetings. On September 11th Sköld had a scheduled meeting with Neutrogena/Johnson & Johnson Pharmaceuticals in New Jersey and a flight that same day to Phoenix, Arizona to see Medicis Pharmaceuticals. Sköld arrived at Johnson & Johnson at 8:45 a.m, but we all know what happened a few miles away at the World Trade Center at 8:46 a.m that frightening day. Sköld's meeting with J&J was postponed and he could not travel to his further appointments since air travel was suspended.

Sköld was therefore stranded in New Jersey, where his cell phone did not function. Per Jeff Day's suggestion, Sköld traveled to Newtown, PA, to a Company called Collagenex, to use their conference room and phone to make needed arrangements.

At Collagenex Sköld was welcomed by its then CEO, Brian Gallagher, together with Rob Ashley and Jeff Day. Before Sköld used the phone, the group had a coffee and talked for 30 minutes or so. The group realized that Collagenex might be interested in my work with RESTORADERM Technology and decided that once Sköld was finished making phone calls the group should continue to discuss a potential partnership. Collagenex was not in dermatology at the time but had one product it was considering bringing to the dermatology community. It wanted to build a range of topical products around this acne product. Since it was that particular awful and emotional day, the group became close to each other with surprising rapidity.

To find an extra measure of meaning in that day, Sköld decided early in those meetings to go to lengths to work with the Collagenex people. During many phone calls with Jeff Day and Rob Ashley thereafter and around the Caribbean meeting on Puerto Rico in January 2002 (where Sköld was attending) Sköld and Collagenex started to negotiate an agreement that eventually (and rapidly) closed in February 2002, as the 2002 Agreement (as identified in the Registrant's First Set of Interrogatories).


Dermatologists with whom Sköld had been working with for some years at that time became a core part of Collagenex scientific board, and Sköld and these dermatologists all worked closely for a number of years putting Collagenex on the dermatology map in the US.

In short, Petitioner entered into the 2002 Agreement because he had established a good relationship with the principles of Collagenex, and because the terms of the agreement, including his understanding of a contingent licensing of the mark RESTORADERM, were satisfactory to him.

VERIFICATION


Thomas Sköld, acknowledging that this verification is made under penalty of perjury, states that he has read the foregoing Petitioner Sköld's Response to Registrant's First Set of Interrogatories, and that to the best of his knowledge, information and belief, the facts set forth therein are true and correct.

DATED: March 15, 2012


Thomas Sköld

Respectfully submitted,

Date: March 15, 2012

By: 

Arthur E. Jackson, Ph.D., Esq.
New Jersey Bar No. 00288-1995
ajackson@moseriplaw.com
MOSEER IP LAW GROUP
1030 Broad Street, Suite 203
Shrewsbury, NJ 07702
(732) 935-7100
(732) 935-7122
Attorney for Petitioner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Thomas Sköld,
Petitioner,

v.


Galderma Laboratories, Inc.,
Registrant

)
)
)
)
) Cancellation No. 92052897
)
)
)

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Petitioner Sköld's Response to Registrant's First Set of Interrogatories, along with the cover letter for the First Updated Initial Disclosures (enclosures by mail), was sent by email on this 15th of March, 2012 to:

Jeff.Becker@haynesboone.com


Arthur E. Jackson

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

Thomas Sköld
Petitioner,

v.

Galderma Laboratories, Inc.
Registrant.

§
§
§
§
§
§
§
§

Cancellation No.: 92052897

Mark: RESTORADERM

Reg. Nos.: 2,985,751 and 3,394,514

EXHIBIT 10

**Portions of Petitioner's Responses to Registrant's Second Set of Interrogatories, served by
Petitioner on Registrant on January 2, 2013.**

k. for each document you contend is privileged or otherwise excludable from discovery, a statement as to the basis for such a claim of privilege or other grounds for exclusion.

I. "Identify," when used with respect to a communication, shall mean:

- a. if the communication is written, the identity of the document(s) in which the communication was made, and the identity of all documents that refer to, relate to, or reflect such communication, or that were discussed, displayed, or used during the communication; and
- b. if the communication was oral, the identity of persons participating in the communication, the date and place where it occurred, its substance, and each person who was present when such statement or communication was made.

J. "On" and "in connection with" mean "on or in connection with."

K. "Or" means "and/or" and the term "and" means "and/or." "Or" and "and" shall be construed conjunctively and disjunctively to bring within the scope of these discovery requests any information that might otherwise be construed to be outside their scope.

L. "Person" or "persons" means any individual, corporation, partnership, association, firm, organization, or entity.

M. "Petitioner" means Thomas Sköld, his predecessors in interest or title, successors, and any and all related companies (as defined by 15 U.S.C. § 1127), as well as all persons acting or purporting to act on his behalf.

N. "Petitioner's Document No. 102" means the single-page document, including the information contained therein, that: (i) Petitioner produced in response to Registrant's First Request for Production of Documents and Things; (ii) bears the heading caption "A theory of the 'mode of action' concerning this new technology"; (iii) bears the date "5 November, 2001"; and (iv) is attached to this Second Set of Interrogatories Exhibit "A."

O. "Petitioner's Document No. 103" means the single-page document, including the information contained therein, that: (i) Petitioner produced in response to Registrant's First Request for Production of Documents and Things; (ii) bears the heading caption "LipoDerm Restoraderm a vehicle technology for topical use"; and (iii) is attached to this Second Set of Interrogatories as Exhibit "B."

P. "Registrant" means Galderma Laboratories, Inc., and its present and former divisions, subdivisions, affiliates, parents, and subsidiary entities, predecessors in interest or title, successors, and any and all related companies (as defined by 15 U.S.C. § 1127), as well as all persons acting or purporting to act on behalf of any of such entities.

Q. "Relating to" means relating to, reflecting, supporting, evidencing, discussing, showing, summarizing, analyzing, containing, pertaining to, or concerning in any way, directly or indirectly.

R. "Technology" means the technology utilizing phospholipid or ceramide, cholesterol, and fatty acid for dermally and transdermally delivering bioactive substances, as discussed in the Amended Petition for Cancellation.

S. "Things" includes any tangible object, including but not limited to audio recordings, video recordings and the like, which may for some reason be construed as something other than documents.

INSTRUCTIONS

1. Registrant requests that Petitioner telephone the undersigned counsel for Registrant if Petitioner believes that any of the discovery requests are over broad or that complying with the request would be unduly burdensome so that the parties can work out a scope for discovery that is commensurate with the needs of the parties in light of the type and quantity of records kept in the ordinary course of business.

2. For purposes of interpreting and construing the scope of the discovery requests made herein, all terms shall be given their most expansive and inclusive interpretation unless otherwise limited by the language of any individual request.

3. In each instance in which an interrogatory is answered upon information and belief, Petitioner shall set forth the basis for such information and belief.

Thomas Sköld v. Galderma Laboratories, Inc.
Cancellation No. 92052897

EXHIBIT A

A theory of the "mode of action" concerning this new technology
5 November, 2001

The vehicle is designed in its choice of and share of lipids to resemble the normal lipid organisation of the stratum corneum. Thus the administered vehicle will easily penetrate the lipid bilayer of the skin and in doing so create a temporary and reversible state of enhanced atrophy among the bilayer.

The enhanced atrophy in itself should then give rise to a) enhanced energy levels, said energy could promote active transport of the to-be-carried substances into the skin, and/or b) naturally and reversibly occurring holes and disorganised patches in the lipid bilayer, through which the active substances could then pass more easily.

It is very well feasible that the temporary disarray in the lipid bilayer will temporarily break up the organised structure of the bilayer and create micelles of lipids with areas between them/ surrounding them through which lipophobic/hydrophilic substances and compositions can enter the stratum corneum.

As the content of the vehicle resembles the natural lipid build-up of the skin, the so introduced new lipids will after a short span of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer and thus not permanently damage the skin.

Thomas Sköld

LipoDerm Lipoid Restoraderm Technology

Thomas Sköld v. Galderma Laboratories, Inc.
Cancellation No. 92052897

EXHIBIT B

CONFIDENTIAL

LipoDerm Restoraderm a vehicle technology for topical use

This technology is a water based lipid product aimed to deliver, to the human body and skin, different active ingredients with a therapeutic value. The lipids that are used are very similar or the same as what is natural existing in the stratum corneum (skin barrier) with an exception of triglycerides, namely palmitin acid, cholesterol and ceramide 3. To this lipids also mevalonic acid is added, a substance that contributes to the lipid biosynthesis. It takes a very small portion of mevalonic acid, in time, to reach the same cholesterol level as if cholesterol is delivered direct to the skin. The lipid content in this technology is only 6-13% and the water content 70-80%, which allows the skin to breath (evaporate) normally. Some active ingredient needs to be dissolved in for example propylene glycol or ethanol and in those cases that amount should be taken out from the water content.

Vehicles has until recently not been given to much credit and products has been developed on either an alcohol or petrolatum base depending on the solubility on the active ingredient. In the treatment of a skin disorder the vehicle can act both positive and negative to the skin. This technology is developed to act as a part of the treatment regime, which means that at the same time as it is delivering the active ingredient it is also restoring the skin barrier function. It is doing that through delivering natural lipids but also, with the lipid biosynthesis, in time help the skin to produce some of them it self.

It is important not to change, too much, the structure and functioning of these lipids. An emulsified fatty acid for an example will not keep its lipid abilities. On the contrary it will act as a detergent instead, which means ability to disrupt the barrier. When formulating, this fact needs to be considered.

For an active ingredient to penetrate the stratum corneum it some time needs help by a "penetration enhancer", which is a substance that will breake the natural lipid pattern and resistance. With chronic use of such a substance one will disrupt the barrier function and the "transepidermal water loss" (TEWL) will increase, which will result in a sensitive skin followed by a skin disorder.

The theory behind this technology is, when the vehicles lipids blends with the lipids of the stratum corneum a very temporarily disorder will occur and the active ingredient can during that time more easily penetrate. This can be explained in more technical terms but future studies can give a more thoroughly explanation/description of what is happening.

Studies that should be done in the nearest 8-12 month are;

- 1, Lipid study tape stripping human skin measuring lipid contents after applications
- 2, Blanching study measuring potency of a hydrocortisone in different vehicles
- 3, Dual action study the effect of the vehicles in chronic hand dermatitis
- 4 Surface anastatical study a comparesant study with other formulations

Interrogatory No. 46:

Describe in detail the “consulting services” in connection with which Petitioner alleges he owns prior rights in the mark RESTORADERM, as stated in paragraph 44 of the Amended Petition.

Interrogatory No. 47:

Describe in detail the target market for Petitioner’s “dermatology product,” as that term is used in paragraph 44 of the Amended Petition.


Interrogatory No. 48:

Describe in detail the target market for Petitioner’s “consulting services,” as that term is used in paragraph 44 of the Amended Petition.

Interrogatory No. 49:

Describe in detail the ways in which the target market for Petitioner’s “dermatology product” differs from the target market for Petitioner’s “consulting services,” as those terms are used in paragraph 44 of the Amended Petition.

Respectfully submitted,



Jeffrey M. Becker, Esq.
Lisa N. Congleton, Esq.
Attorneys for Registrant
HAYNES AND BOONE, LLP
2323 Victory Avenue, Suite 700
Dallas, Texas 75219
Telephone: 214-651-5262
Facsimile: 214-200-0765
jeff.becker@haynesboone.com
lisa.congleton@haynesboone.com

Date: January 2, 2013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Registration Nos. 2985751; and 3394514

Dated: August 16, 2005 & March 11, 2008, Respectively

Thomas Sköld,)	
Petitioner,)	
)	
v.)	
)	Cancellation No. 92052897
Galderma Laboratories, Inc.,)	
Registrant)	

**PETITIONER SKÖLD'S RESPONSE TO REGISTRANT'S SECOND
SET OF INTERROGATORIES**

Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure, Petitioner Thomas Sköld ("Sköld"), by and through its undersigned counsel, submits this response to the Registrant's First Set of Interrogatories as set forth below.

As a general note, applicable to multiple Interrogatories, Petitioner's RESTORADERM Technology is based on (a) compositions of stratum corneum lipids (phospholipids/ceramide/ cholesterol/fatty acid), and (b) the presence of different macromolecular aggregates formed of the lipids. Its primary intent is for formulation for delivering pharmaceutically active substances into or through the dermis of a patient. But Sköld's use of the trademark has extended to the vehicle. References herein to the "RESTORADERM Technology" are references to technology encompassing (a) and (b).

As a general note, the responses below may speak of "Registrant," where the context should make clear whether the referenced party was, at the time of events recited, Galderma Laboratories, Inc. ("Galderma") or its predecessor in interest, Collagenex Pharmaceuticals, Inc. ("Collagenex"). At other times, the specific such party may be called out.

Petitioner's response to the Requests is made to the best of Petitioner's current knowledge, information, and belief. This response is at all times subject to such additional or different information that discovery or further investigation may disclose and, while based on the present state of Petitioner's recollection, is subject to such refreshing of recollection, and such additional knowledge of facts; as may result from Petitioner's further discovery or investigation.

Petitioner objects to these interrogatories to the extent that they seek to impose burdens or obligations inconsistent with, or in excess of, those imposed by the Federal Rules of Civil Procedure, title 37 of the Code of Federal Regulations, the TTAB Manual of Procedure, or any other applicable rules and statutes.

Additionally, Petitioner objects to each interrogatory to the extent that it calls for the disclosure of material or information protected by one or more of the attorney-client privilege, work-product doctrine, or any other applicable privilege.

Interrogatory No. 32:

Identify each document that Petitioner produced to Registrant in this proceeding that is not a true and correct copy of an authentic document, if any.

Response:

On information and belief, every document produced is believed to be a true and correct copy of an authentic document.

Interrogatory No. 45:

Describe in detail the "dermatology product" in connection with which Petitioner alleges he owns prior rights in the mark RESTORADERM, as stated in paragraph 44 of the Amended Petition.

Response:

The dermatological products are (a) dermatological compositions based on (i)

compositions of stratum corneum lipids (phospholipids and/or ceramide, cholesterol and fatty acid), and (ii) the presence of different macromolecular aggregates formed of the lipids, and (b) various such formulations adapted for dermal or transdermal delivery of pharmaceutically active substances, as described in U.S. Pat. 8,029,810, and corresponding patent documents for other countries. Beyond the answer provided, Petitioner objects to this Interrogatory as unduly burdensome

Interrogatory No. 46:

Describe in detail the “consulting services” in connection with which Petitioner alleges he owns prior rights in the mark RESTORADERM, as stated in paragraph 44 of the Amended Petition.


Response:

The consulting services are with respect to providing and formulating the goods described above, and ancillary services as would be anticipated for a person well connected in the Dermatology community. Beyond the answer provided, Petitioner objects to this Interrogatory as unduly burdensome.

VERIFICATION

Thomas Sköld, acknowledging that this verification is made under penalty of perjury, states that he has read the foregoing Petitioner Sköld's Response to Registrant's Second Set of Interrogatories, and that to the best of his knowledge, information and belief, the facts set forth therein are true and correct.

DATED: February 6, 2013



Thomas Sköld

Respectfully submitted,

Date: February 7, 2013

By: / Arthur E. Jackson /

Arthur E. Jackson, Ph.D., Esq.
New Jersey Bar No. 00288-1995
ajackson@moseriplaw.com
MOSER IP LAW GROUP
1030 Broad Street, Suite 203
Shrewsbury, NJ 07702
(732) 935-7100
(732) 935-7122
Attorney for Petitioner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Thomas Sköld,
Petitioner,

v.

Galderma Laboratories, Inc.,
Registrant

Cancellation No. 92052897

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Petitioner Sköld's Response to Registrant's Second Set of Interrogatories, along with the cover letter for the First Updated Initial Disclosures (enclosures by mail), was sent by email on this 7th of February, 2013 to:

Jeff.Becker@haynesboone.com


Arthur E. Jackson